Open AccessA new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC
Author(s) -
Lu Yue,
Fan Zhenzhen,
Zhu SuJie,
Huang Xiaoxing,
Zhuang Zhongji,
Li Yunzhan,
Deng Zhou,
Gao Lei,
Hong Xuehui,
Zhang Ting,
Li Li,
Sun Xihuan,
Huang Wei,
Zhang Jingfang,
Liu Yan,
Zhang Baoding,
Jiang Jie,
Gui Fu,
Wang Zheng,
Li Qiyuan,
Song Siyang,
Huang Xin,
Wu Qiao,
Chen Lanfen,
Zhou Dawang,
Zhang Jianming,
Yun CaiHong,
Chen Liang,
Deng Xianming
Publication year - 2021
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.15252/emmm.202114296
Subject(s) - crizotinib , alk inhibitor , anaplastic lymphoma kinase , cancer research , in vivo , chemistry , pharmacology , lung cancer , biology , medicine , genetics , malignant pleural effusion
More than 60% of nonsmall cell lung cancer (NSCLC) patients show a positive response to the first ALK inhibitor, crizotinib, which has been used as the standard treatment for newly diagnosed patients with ALK rearrangement. However, most patients inevitably develop crizotinib resistance due to acquired secondary mutations in the ALK kinase domain, such as the gatekeeper mutation L1196M and the most refractory mutation, G1202R. Here, we develop XMU‐MP‐5 as a new‐generation ALK inhibitor to overcome crizotinib resistance mutations, including L1196M and G1202R. XMU‐MP‐5 blocks ALK signaling pathways and inhibits the proliferation of cells harboring either wild‐type or mutant EML4‐ALK in vitro and suppresses tumor growth in xenograft mouse models in vivo . Structural analysis provides insights into the mode of action of XMU‐MP‐5. In addition, XMU‐MP‐5 induces significant regression of lung tumors in two genetically engineered mouse (GEM) models, further demonstrating its pharmacological efficacy and potential for clinical application. These preclinical data support XMU‐MP‐5 as a novel selective ALK inhibitor with high potency and selectivity. XMU‐MP‐5 holds great promise as a new therapeutic against clinically relevant secondary ALK mutations.